Many methods such as selective inhibition,' electrophoresis.' high performance liquid chromatography (HPLC),3 and the use of specific monoclonal antibodies4,' have been described for the measurement of intestinal alkaline phosphatase (ALP). We have developed an assay for intestinal ALP utilizing the magnetic separation reagent and phenolphthalein monophosphate (PMP) substrate developed by Serono for the Miaclone"" range of enzyme immunoassays. This technique was adopted for the assay of human intestinal ALP by the use of a specific anti-intestinal monoclonal antibody labelled with fluorescein isothiocyanate (FITC).
A specific assay for serum intestinal alkaline phosphatase utilizing fluorescein labelled monoclonal antibody and antifluorescein antibody coupled to magnetic particles P Scott and G A Maguire Many methods such as selective inhibition,' electrophoresis.' high performance liquid chromatography (HPLC),3 and the use of specific monoclonal antibodies4,' have been described for the measurement of intestinal alkaline phosphatase (ALP). We have developed an assay for intestinal ALP utilizing the magnetic separation reagent and phenolphthalein monophosphate (PMP) substrate developed by Serono for the Miaclone"" range of enzyme immunoassays. This technique was adopted for the assay of human intestinal ALP by the use of a specific anti-intestinal monoclonal antibody labelled with fluorescein isothiocyanate (FITC).
MATERIALS AND METHODS
Magnetic separation reagent, stop solution and FITC were kindly donated by Serono Diagnostics, Woking, Surrey, UK. The monoclonal antibody (as mouse ascites) was the kind gift of Dr J P Luzio.' An immunoglobulin fraction was prepared from the mouse ascites by sodium sulphate precipitation' and conjugated with FITC6 to give a final molar FITC: protein ratio of 5 : 1. Intestinal alkaline phosphatase (intestinal ALP) was prepared by the solubilization in 2% SB14 and 200 mmol/L Tris (pH 6.4) of an intestinal mucosal scrape of a piece of small intestine obtained post mortem.
Duplicate 25pL aliquots of serum or control were incubated for 30min a t 37°C with 25 p L of FITC-labelled anti-intestinal ALP antibody (0.3 mg/mL). Separation reagent (300 p L of Serono anti-FITC antibody coupled to magnetic particles) containing 20 mg/L bovine serum albumin (BSA), was then added and the tubes were incubated for 30 min at 37°C. The magnetic Correspondence: Dr G A Maguire particles were pelleted by leaving for 10 min on a magnetic separator, then washed twice with 1 mL of wash solution (1 0 mmol/L Tris, pH 7.4, 20 mg/ L BSA and 0.1% Triton x 100). After draining, 300pL of PMP substrate (Serono) was added, and the tubes were incubated for 2 h at 37°C. Stop solution (1 mL, Serono) was then added, and the tubes were left at room temperature for 15 min on the magnetic separator. Absorbance was then measured at 550nm in a Serozyme I analyser (Serono Diagnostics) and the activity (U/L) of intestinal ALP calculated from the absorbance change per minute. N o calibrant was required for the assay. The concentrations of antibodies used were sufficient to precipitate all intestinal ALP in specimens to which up to 80 U/L of intestinal ALP were added.
RESULTS
The between batch precision ("/,CV) at 9.5, 5.0 and 1.6 U/L was 6.2, 7.1 and 11.7, respectively. The within batch standard deviation (estimated from the difference e duplicates of the samples, SD,,, = assay was linear up to 80 U/L of intestinal ALP. The detection limit (3 x S D of a low activity specimen) was O.O39U/L. There was no crossreaction with placental ALP up to at least lOOO.U/L added to a specimen. Cross-reaction with liver ALP was not expected since liver ALP is immunologically distinct from intestinal ALP. It was not possible to directly demonstrate this (since human liver ALP was not available) but the antibody was shown not to remove liver ALP from a specimen.
The reference range (5th to 95th percentile) of specimens from 108 non-fasting males and 92 females was 0.25 to 8.28 U/L of serum intestinal ALP; similar to that observed in previous studies.' Intestinal ALP levels varied with blood group. The distribution were neither Gaussian nor log-Gaussian so the Mann-Whitney U test was used. Subjects with blood group A had sig- (Table I) . Males had somewhat higher levels (median 2.33 U/L: observed 95% confidence limits 0.29-10.34 U/L of intestinal ALP) than females (medium 1.45 U/L; observed 95% confidence limits 042-10.54 U/L), but this diffcrence was not statistically significant.
Blood group

DISCUSSION
We have dcvelopcd an assay for intestinal ALP based on reagents developed for the Miaclone'"' rangc of enzyme immunoassays using a specitic monoclonal anti-intcstinal antibody labelled with FITC. This mcthod offers ccrtain improvements over previously published methods. Thc levamasole inhibition method though precise is not accurate. particularly when placental ALP is present. HPLC' requires a large sample volume (100-400pL) and does not give very good resolution of thc intestinal ALP peak from the first bone ALP peak, discrimination of these two peaks requiring the use of inhibition techniques. Electrophoretic methods are usually only qualitative.' Previous mcthods have been described in which monoclonal antibodies have been used. The one described by Hirano et using antibody conjugated to paper discs is precisc at very high intentinal ALP concentrations, but the within-batch precision at low concentrations. linearity and dctection limit were not specified. The assay described by Bailyes cat requircs the preprecipitation of livcr/bone and placental ALP prior 10 capture of the anti-intestinal ALP on multiwcll platcs. In common with some previous studics5~' we found that individuals of blood group A had significantly lower levels of intestinal ALP than any of the other groups. Bayer et al.' explained this finding by postulating that intestinal ALP binds to erythrocyte membranes, and that this removal is blood group dependent, group A erythrocytes having a higher affinity for intcstinal ALP than the other groups, leading to quicker elimination and lower serum intestinal ALP. It is interesting to note that the AB individuals. who would have half the amount of A antigens on their red cells. had an intestinal ALP intermediate between that of group A and groups B and 0. Although the difference was not statistically significant as only 10AB individuals were studied, the observation is consistent with the findings of Bayer et al. ' Having developed an assay for intestinal ALP that is simple, specific, precise, has a detection limit of 0.039 U/L is linear to 80 U/L and uses commercially available products that are very stablc, we will now be able to conduct clinical studies to establish the role of intestinal ALP in the diagnosis and monitoring of disease.
